Covers hair and nail findings, vision loss lawsuits Novo and Lilly dispute, and new WHO guidance against obesity drugs for kids under 10.
Recap by typeshit. Full story at MIT Technology Review.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
In a survey of 1,904 people, 39% of users reported nail detachment, against 9% of non-users. The authors say the design can't show the drugs caused it.
Gizmodo covers a possible link between Ozempic and slower aging. The study itself and what it measured aren't described in the material given.
Loading…